196
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment

ORCID Icon, , ORCID Icon, ORCID Icon, , , , ORCID Icon & show all
Pages 1609-1618 | Received 26 Nov 2020, Accepted 26 Jan 2021, Published online: 24 Feb 2021
 

Abstract

Classic Hodgkin lymphoma (cHL) in young children (ages 0–6) is rare in high income countries (HICs) but is more prevalent in low- and middle-income countries (LMICs) like Guatemala. Given that the majority of cHL studies have evaluated adolescent/adults, and the immune system changes with age, we sought to characterize Epstein-Barr virus (EBV) expression, immune regulatory pathway markers and the tumor microenvironment in 42 children ages 0–6 with cHL from Guatemala. We found a very high frequency of EBV expression (97.5%). Hodgkin cells showed increased expression of PD1 ligands and CD137, indicative of shared immune regulatory mechanisms with adult cHL. Pediatric cHL also showed an increase in CD8+ tumor infiltrating lymphocytes and tumor associated macrophages within the tumor microenvironment. Despite 25 having high risk disease, only 4 patients died from progressive disease, relapse or infection.

Author contributions

O.S. performed experiments, analyzed data and drafted the manuscript. V.C. analyzed data and drafted the manuscript. M.E. and R.M. performed experiments. M.E.C. provided clinical information and samples. S.Z. performed experiments. S.L.F. designed experiments and drafted the manuscript. Y.N. designed experiments, performed experiments, analyzed data and drafted the manuscript.

Disclosure statement

The authors have no conflict-of-interests to declare.

Data accessability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.